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ABSTRACT: The fields of molecular cell biology and human genetics have recently experienced 
several revolutions that have brought new knowledge and new technologies. Large scale sequen-
cing and global functional characterization studies allow simultaneously monitoring thousands 
of sequences and molecules, thus generating a large amount of data giving a real-time molecular 
details snapshot of an individual. In this review we briefly refer to some of these novel techni-
ques, including next-generation sequencing methods and CRISPR/Cas9 editing gene systems. The 
major applications and implications of these novel technologies in research and molecular diag-
nostics are presented. Ethical issues raised by the implementation of these methods in healthcare 
systems in the near future are discussed.
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Metodologias emergentes de larga escala na era pós-genómica: benefícios 
e questões éticas
RESUMO: As áreas da biologia celular e molecular e da genética humana sofreram recente-
mente uma grande revolução que trouxe novo conhecimento e novas tecnologias. Os estudos de 
sequenciação em larga escala e de caracterização funcional permitem a monitorização simultânea 
de milhares de sequências e moléculas, gerando uma grande quantidade de dados e fornecendo 
detalhes moleculares em tempo real e de modo instantâneo de um indivíduo. Nesta revisão faz-se 
uma referência breve a algumas destas novas técnicas, incluindo os métodos de sequenciação de 
next-generation e os métodos de edição de genes baseados no sistema CRISPR/Cas9. São apresen-
tadas as potenciais aplicações e implicações destas novas tecnologias nas áreas de investigação e 
diagnóstico molecular. São também discutidas as questões éticas levantadas pela implementação 
destas metodologias num futuro próximo.
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Introduction
Technical advances in the last decade in molecular cell 
biology and human genetics created the possibility to 
analyse samples on a systems level. Therefore, over the 
past few decades the use of the ‘omics’ suffix has become 
familiar especially when the human genome sequence was 
completed in the early 2000s. It rapidly expanded beyond 
use for genomics and proteomics to other areas, and terms 
like transcriptomics, metabolomics, epigenomics, interacto-
mics and pharmacogenomics started to flood the scientific 
works. In fact, this was the consequence of being possible 
to use ‘omics’-based approaches not only to current but also 
to emerging research fields. The possibility to ‘have global 
pictures’ of an individual in a short period of time in oppo-
sition to look, for example, at a single gene or a few compo-
nents of a cell signalling pathway of an individual, changed 
the way of doing research (cf. Figure  1). ‘Omics’ approaches 
accept that a complex system can be better understood if 
considered as a whole. While more traditional approaches are 
largely hypothesis-driven, the ‘omics’ experiments are essen-
tially hypothesis-generating. In this case, holistic approaches 
are used without a predefined hypothesis, but all data are 
acquired and analysed to define a hypothesis that can be 
further tested. The two approaches are not mutually exclusive 
but instead are complementary1. 
6The implications of these new approaches to the field of 
biomedical sciences opened incredible new possibilities to 
understand the molecular mechanisms underlying human 
diseases and therefore to envisage new strategies of diag-
nosis, prognosis and therapy. Moreover, the ability to study 
biological phenomena at ‘omics’ levels lead to a new para-
digm in healthcare by shifting the idea of conventional medi-
cine from ‘one-size-fits-all’ approach to one based in indivi-
dual characteristics – Precision medicine. In conventional 
medicine disease treatment and prevention strategies are 
developed for the average person, with little consideration 
for the differences between individuals. Thus, according to 
the National Institutes of Health (NIH, USA) (https://ghr.nlm.
nih.gov/) precision medicine is an “emerging approach for 
disease treatment and prevention that takes into account 
individual variability in genes, environment, and lifestyle for 
each person”. This new approach will predict more accurately 
which treatment and prevention strategies for a disease will 
work better in which groups of people.
In this review we will briefly describe some of the major 
technological advances in biology and refer to their impact 
in the biomedical field. We will subsequently refer to the new 
ethical challenges posed by them.
Novel technologies that allow exploring and editing the 
human genome
A variety of molecular technologies have been developed in 
this century paving the way to bioscience and medical advan-
cements and providing new avenues for scientific research.
Next generation sequencing (NGS), massively parallel 
or deep sequencing is related terms that describe a DNA 
sequencing technology, which has revolutionized genomic 
research. In contrast to the previous Sanger sequencing tech-
nology, used to decipher the human genome, which required 
over a decade to deliver the final draft in 20012-3, using NGS, 
an entire human genome can be sequenced within a single 
day.
Within the genomic analysis performed by NGS, it is 
possible to study inherited variation or somatic mutations 
by whole-genome sequencing (WGS) or whole-exome 
sequencing (WES). In whole-genome sequencing, somatic 
mutations, including, single nucleotide polymorphisms or 
insertion-deletion mutations are identified by sequencing 
the entire genome. This approach has been used to identify 
several somatic mutations in cancers4. The whole-exome 
sequencing is used to analyse a specific targeted subset 
within the protein-coding sequences, the exons. In the clinic, 
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Figure 1. Simplified scheme of ‘Omics’ impact in human health care and ethical issues.
In the post-genomic era, the “physiology and anatomy” of the human genome i.e., its functionality, has been exploited by large-scale approaches, 
from genomics to transcriptomics and epigenomics and from proteomics to metabolomics and interactomics. The generated information has been of 
great value in biomedical sciences, namely for a more precise diagnosis and therapeutics towards individual characteristics. However, the secondary 
information generated can raise several issues, including ethical ones that need to be carefully addressed.
7whole-exome sequencing has been increasingly used to 
assign patients with an unclear diagnosis to a known disease, 
usually, Mendelian monogenic diseases5.
Importantly, one of the earliest applications of NGS was to 
create ‘epigenomic maps’, showing the location of specific 
DNA modifications, chromatin modifications and protein-
-binding events across the human genome. The sites of DNA 
methylation can be found by sequencing DNA in which 
the methylated cytosines have been chemically modified 
(methyl-seq)6, whereas chromatin (histone) modifications 
and protein binding to target DNA sequences (e.g., transcrip-
tion factor binding to gene promoters) can be mapped by 
chromatin immunoprecipitation-sequencing (ChiP-Seq)7-8.
Sequencing is also being extensively applied to RNA trans-
cripts (RNA-seq) to determine their abundance, identity or 
detect novel splice forms, thus contributing to transcriptome 
analysis9. RNA-seq is mainly used for sequencing mRNAs 
or long noncoding RNAs (lncRNAs). A more recent variant 
of transcript analysis, miRNA-seq, has been applied to the 
specific detection and quantification of small non-coding 
microRNAs. These regulate gene expression by targeting 
mRNAs for translational repression, degradation, or both that 
have emerged as important modulators in cellular pathways, 
such as growth and proliferation, apoptosis, and develop-
mental timing10.
Both RNA-seq and miRNA-seq have been used for studying 
gene expression patterns unique to certain cancers and, 
in the case of miRNA, in cardiovascular diseases, enabling 
researchers to identify clinically relevant novel biomarkers 
for specific types of cancer and predictors of cardiovascular 
diseases11-14.
In addition to the extensive genome ‘anatomy and physio-
logy’ provided by ‘omics’ methods, genomes have also been 
subject to engineering. The so-called ‘molecular scissors’ 
that allow targeted changes to genomes of living cells have 
evolved along time and are recently based on the system 
(CRISPR – clustered regularly interspaced palindromic 
repeats)/CRISPR-associated 9 nuclease (Cas9) (CRISPR/
Cas9)15. In a simplified way, by delivering the Cas9 nuclease 
complexed with a synthetic guide RNA (gRNA) into a cell, the 
cell’s genome can be cut at a desired location, allowing exis-
ting genes to be removed and/or new ones added16. This new 
genome editing tool has many potential applications in medi-
cine, namely at the field of gene therapy but also raises some 
important ethical issues, which are further discussed below.
Impact of large-scale sequencing and genome editing in 
biomedical sciences
The genome-wide based methods have an enormous 
potential on biomedicine. Some of the most relevant 
outcomes of these methods are briefly described in this 
section.
With the emergence of NGS methods, a major advance 
was carried out in what refers to characterization of genomic 
variation. Indeed it is now possible for geneticists to assay 
a very large number of SNPs in an individual. Those genetic 
variants common enough in populations could be annotated 
and examined for association with phenotypes and inter-
preted in clinical settings17. The new sequencing technolo-
gies should also be able to identify novel genes responsible 
for undescribed Mendelian disorders in patients with unex-
plained congenital conditions18. Moreover, the comparison of 
patients and parents genomes will make it possible to spot 
new mutations. This approach has the potential to be used 
in prenatal counselling by characterizing germline genomes. 
Polygenic diseases can also be further characterized through 
a combination of GWAS (gene wide association studies 
focused on associations between SNPs) and sequencing. 
Coupled with functional studies, namely the generation of 
mouse models, these methods will help characterizing the 
phenotype of common disorders.
Cancer gene discovery is also being driven by systematic 
genome-wide efforts, involving the combination of DNA 
sequencing, copy-number analysis, gene expression analysis 
and functional studies such as RNA interference. These 
combined efforts are promoting the grouping of hetero-
geneous tumours into homogenous sub-groups based on 
mechanism19. The generation of a comprehensive list of all 
somatic mutations in human cancer cell types will allow defi-
ning novel drug targets and generating animal models that 
will be the basis of novel clinical trials.
The application of genome-wide studies to Immunology 
will help determining the patterns of B-cell and T-cell recep-
tors in different settings20, thus making it possible to recons-
titute immune repertoires and monitor responses to vaccines 
or infer disease exposures. Also, microbiomes are starting 
to be characterized by NGS21 and further characterisation 
and association of patterns of microbial communities with 
diseases processes will be of major clinical interest. Impor-
tantly, the impact of microorganisms in human health can 
also be monitored by assessing their presence in different 
environments.
Furthermore, NGS can have applications in pharmacoge-
nomics, the ability to predict the response to drugs or their 
adverse effects in a personalized way, according to the infor-
mation of each patient’s genome as reviewed in22.
In a different perspective, maps of genetic variation among 
human populations provided by genomic data will also contri-
bute to unveiling human history and the migration of popu-
lations23, thus reshaping our understanding of the peopling 
of the globe. It can also contribute to find differences to our 
closest relatives, such as Neanderthal and chimpanzee. This 
valuable information can be used to reconstruct several 
events of human history, from the structure of the ancestral 
human population in Africa to the subsequent population 
dispersals and impact of selection (natural or human-me-
diated) in civilization.
Regarding genome editing, major improvements are still 
required before molecular scissors, such as the CRISPR/Cas9 
platform described above, can be implemented in genomic 
medicine. Several factors can affect the efficacy of treat-
ment, including the genetic nature of a disease, the required 
correction, the delivery method and the targeted cells and 
organs24. Nevertheless, this technology has several potential 
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8applications. The targeted gene therapy, mediated by mole-
cular scissors involves manipulation of the genetic material 
either to delete and replace causal mutations or to induce 
host mutations that can provide protective functions. Mono-
genic diseases are thus the most easy to treat this way, since 
the generation of a dysfunctional copy of the causative gene 
would reverse the disease state25. On the other hand, poly-
genic diseases, that require simultaneous multiple alterations 
of the genome are more challenging to treat. The growing 
knowledge of genomes will allow the complete understan-
ding of the genetic basis of these polygenic diseases, making 
it possible to subject to multiple genomes editing that will 
eventually dictate a desired genetic outcome that can reverse 
the illness. In this context CRISPR/Cas9 system could be used 
in the treatment of complex diseases such as cancer. Cancer 
genomes and epigenomes in various cells are very complex, 
with several SNPs and chromosomal rearrangements. Thus 
the CRISPR/Cas9 system would be useful, in this case to gene-
rate ‘next-generation-mouse-models’ in which genetic alte-
rations are combined to mimic cancer states26. This model 
would be a valuable tool to validate cancer-related genes 
identified in The Cancer Genome Atlas. Ultimately, the fact 
that the CRISPR/Cas9 system was initially discovered as a 
molecular immunity mechanism against invading pathogens 
might suggest that it would also be a good system for gene 
therapy against AIDS or other diseases caused by viral infec-
tions, namely those associated with cancers, such as hepatitis 
virus B and C in liver cancers27.
Some ethical and social implications: the individual 
genomic data, privacy and discrimination
In the last years the application of precision medicine 
approaches to diseases in areas like oncology, psychiatry and 
cardiovascular conditions started to be a reality. For example 
in oncology a number of diagnostic tests have already been 
established as clinical prognostic factors (such as gene expres-
sion profiling assays for breast and colorectal cancer and the 
long-QT syndrome panel) and targeted therapeutics (e.g., 
trastuzumab and irinotecan)28. Therefore, we are gradually 
observing the precision medicine movement entering clinical 
settings. In addition to these significant advances and increa-
sing potentialities we should be aware that this will also be 
accompanied by ethical, legal and social implications. The 
large amount of data generated by genome-wide approaches 
creates new challenges to the way how this data are gene-
rated, collected, analysed and stored. This process may raise 
issues related to privacy and discrimination. In fact, if private 
health information is inappropriately disclosed this could 
lead to individual discrimination and stigma. This may also 
affect the individual confidence relationship with physician 
and other healthcare providers, which may lead to altered 
behaviours as hiding critical information which will affect the 
treatment. There is also the risk of these problems becoming 
a public health threat, e.g. if the individual has an infectious 
disease or mental illness29.
Another ethical problem related to the data is the fact that 
new sequencing technologies, generate additional infor-
mation This raises the ethical issue of what should be done 
with WES and WGS “secondary” findings (e.g., carrier status 
for recessive diseases, cancer predisposition mutations, 
early-onset disease and late-onset disease, etc.) and if they 
should be or not communicated to the patient. An interes-
ting discussion of this problem was conducted by Hallowell 
and coworkers30, concluding that the process requires full 
transparency of the purpose of the sample to be collected. 
Clear protocols for data transfer between research and clinical 
contexts and accurate information to the patients are also 
required. Patients should be aware that secondary informa-
tion may be generated and which are the options of posterior 
action in the clinical context.
Furthermore the new ‘omics’ approaches have the poten-
tial to go further in finding differences between individuals, 
opening a new avenue to ‘genetic discrimination’ in employ-
ment, insurance, mortgages or other activities, because they 
can easily correlate ‘differences’ with putative economic losses 
(for discussion see31). For example, genomic data can inform 
if an individual has the susceptibility to develop a certain 
disease and if this individual belongs to a genetic group that 
will not be successfully treated with standard medications, 
therefore representing an increased morbidity, mortality risk 
and higher health costs. Moreover, the genome has essen-
tial features that allow identification (e.g., forensics) and the 
potentiality to exposure family relationships, which will affect 
not only the individual but other relatives. Also, direct-to-con-
sumer DNA testing increases the probability that genome 
data will be made available on the internet and for-profit 
companies, that can be both considered less regulated envi-
ronments.
In conclusion we can envisage that in a near future genome 
sequencing will become a routine practice, which will have 
a profound impact in medicine, with fast widespread usage 
of genomic information by health care systems. The mainte-
nance of data confidentiality and individual privacy should 
be a central concern even before this system is established. 
However, we are far from being prepared to deal with these 
issues, as recently demonstrated by the establishment of an 
NIH working group to manage access to HeLa cell genomic 
data32. Our present limitations to assure the privacy of partici-
pants in genomics studies have been reported and discussed 
in a few recent papers33-34.
Our challenge is therefore to simultaneously guarantee the 
security and privacy of genomic data, without significantly 
compromising its use in research and health care (cf. Figure 1). 
These will require clear policies and legislation to protect 
individual data and the simultaneous commitment of the 
computer sciences in cross-talk with geneticists and health 
care providers to develop efficient and secure bioinformatics 
techniques to deal and store big genomic data.
Social and economic inequalities, transmitted to subse-
quent generations, result in the indefensible persistence 
of health inequalities35
The possibility to implement precision medicine in heal-
thcare services has raised the discussion of weather this 
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9new approach will contribute to the elimination of health 
disparities or instead to accentuate inequalities. Tailoring 
medical treatment decisions to an individual’s genetic profile 
is thought to decrease costs resulting from ineffective treat-
ments and medicines. In the precision medicine approach 
an important component of health-care delivery is disease 
prevention. This requires risk assessment relying in indivi-
dual genetic information, the use of biomarkers and addi-
tional information like family history of a given disease, life 
style, age, etc. In publically funded health-care systems, the 
use of risk assessment may allow establishing thresholds 
that will be used to decide who is going to have access to a 
given treatment or to an additional screening. At first glance 
this approach seems to contribute to lower the health costs 
and a better distribution of limited resources but may have 
a perverse effect denying excluded individuals to also access 
accurate health care.
Precision medicine may create or accentuate disparities in 
the near future related to costs of new healthcare technolo-
gies implementation that will not be available for all the indi-
viduals at the beginning (cf. Figure 1). Brothers et al.29 discuss 
that although this in general occurs when new technologies 
are introduced, it is possible that in the case of countries that 
have national healthcare services these new approaches may 
be slowly embraced. In fact, the healthcare systems generally 
limit coverage to treatments with well-established efficacy. 
Thus, it is likely that new precision medicine technologies 
will be first available at private health institutions making it 
only accessible to small groups of the population that are 
able to afford them. Based on this scenario some authors 
support that the ethical ways of using emerging genomics 
knowledge, namely in pharmacogenetics, would be to care-
fully define genetic differences between populations instead 
of strengthening an individualistic ‘boutique-style’ model of 
healthcare36.
Finally the new health paradigms may originate health 
disparities in society and between distinct populations 
through the establishment of completely computerized 
health care services. It is already a reality that individual health 
records are instantaneously available to different health 
services and patients may receive their clinical test results by 
email. In a near future, individuals will be encouraged to have 
a more active participation in their health care by monitoring 
their health status, as well as by adjusting treatments to their 
daily requirements. This requires that patients have access 
to information technologies and know how to work with it. 
Therefore a patient can only benefit from this if he/she has 
access to internet services and an internet capable device, as 
well as the necessary computer literacy. On the other hand, 
these new realities may be advantageous for health services 
in most remote areas by the easily delivery of knowledge 
and techniques. Thus the scenario is complex and implemen-
tation should be thoroughly analysed and adjusted to the 
population needs and specificities.
Concluding remarks
New high-throughput ‘omics techniques are providing 
exciting opportunities in clinical medicine but present new 
ethical challenges and are changing the traditional rela-
tionships between patients and health care professionals and 
services. This will require not only that patients will be able 
to understand the new provided information but also that 
medical doctors and other healthcare providers will need to 
know more about molecular genetics and biochemistry35. 
They will increasingly face the need to interpret the results of 
genetic tests, understand how that information is relevant to 
treatment or prevention approaches, and convey this know-
ledge to patients.
The ability to modify genomes of living organisms at precise 
locations in more specific ways is now a reality by using 
techniques such as CRISPR-Cas9. This raises effective possi-
bilities to gene therapy at low costs. However this powerful 
technology would create major ethical concerns if it were 
used to edit germline genome that change gene(s) beyond 
a single generation impacting humans and environment. This 
has lead the European Group on Ethics in Science and New 
Technologies to release a statement in 2016 on gene editing 
asking for a broad public debate in this subject37.
Finally, although this is not the focus of our review, we 
want to conclude that in the post-genome era the research 
process is also facing new ethical challenges. This subject is 
excellently reviewed and analyzed by Vähäkangas38 who ends 
the review with a remarkable text that we cannot fail to cite as 
professors and scientists: Individual scientists, scientific jour-
nals, universities and research institutions, as well as society at 
large, have an essential role in keeping science independent, 
transparent and self-correcting. Not only fraud, but also care-
lessness, poor validation, and poor quality control of methods 
and data violate good scientific practice. We, the senior scien-
tists and the institutions we lead and manage, are responsible 
for the transfer of research tradition to the next generation 
of scientists through education, mentorship and setting an 
example by our own behavior, as well as by creating systems 
that support good research ethics.
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